These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33519187)

  • 1. Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis.
    Pessoa B; Malheiro L; Carneiro I; Monteiro S; Coelho J; Coelho C; Figueira J; Meireles A; Melo Beirão JN
    Clin Ophthalmol; 2021; 15():253-260. PubMed ID: 33519187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab.
    Lim LS; Ng WY; Mathur R; Wong D; Wong EY; Yeo I; Cheung CM; Lee SY; Wong TY; Papakostas TD; Kim LA
    Clin Ophthalmol; 2015; 9():1715-8. PubMed ID: 26396494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of the efficacy of early switching from bevacizumab to aflibercept or ranibizumab in diabetic macular edema.
    Ataş M; Ozsaygılı C; Bayram N; Unal S
    Eur J Ophthalmol; 2022 Nov; ():11206721221137164. PubMed ID: 36330651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema.
    Alsaedi NG; Alselaimy RM; Alshamrani AA; AlAjmi M; Khandekar R; Al-Dhibi H; Al-Abdullah AA
    Clin Ophthalmol; 2021; 15():2975-2980. PubMed ID: 34285463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.
    Salimi A; Vila N; Modabber M; Kapusta M
    Indian J Ophthalmol; 2021 Feb; 69(2):360-367. PubMed ID: 33463593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies.
    Xiao K; Li FZ; Liang SZ; Wang J; Qian C; Wan GM
    Ann Pharmacother; 2020 Aug; 54(8):750-756. PubMed ID: 32005079
    [No Abstract]   [Full Text] [Related]  

  • 13. [Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months].
    Holbach B; Zeman F; Helbig H; Gamulescu MA
    Ophthalmologe; 2020 Jul; 117(7):687-692. PubMed ID: 31705192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravitreal aflibercept on recalcitrant diabetic macular edema.
    Klein KA; Cleary TS; Reichel E
    Int J Retina Vitreous; 2017; 3():16. PubMed ID: 28373914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion.
    Ozgonul C; Dedania VS; Besirli CG
    J Ocul Pharmacol Ther; 2018 May; 34(4):340-345. PubMed ID: 29447089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
    Bro T; Hägg S
    Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
    Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
    Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
    Wood EH; Karth PA; Moshfeghi DM; Leng T
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye.
    Bakbak B; Ozturk BT; Gonul S; Yilmaz M; Gedik S
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):728-32. PubMed ID: 23848950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.